Welcome to our dedicated page for Tvardi Therapeutics SEC filings (Ticker: TVRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tvardi Therapeutics, Inc. (NASDAQ: TVRD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tvardi’s filings describe it as a Delaware corporation and a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Through documents such as Form 8-K current reports, investors can review Tvardi’s announcements regarding financial results, business updates, executive and director changes, compensation arrangements, and key clinical and corporate events. Recent 8-K filings have covered quarterly results, updates on preliminary data from the REVERT IPF Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis, the availability of updated corporate presentations, and the adoption of a severance and change in control plan and retention equity awards for certain employees.
Registration statements on Form S-1/A offer additional detail on Tvardi’s business following its merger with Legacy Tvardi, the change of name from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc., and the commencement of trading on The Nasdaq Capital Market under the symbol TVRD. These filings also outline the company’s status as a smaller reporting company and its focus on STAT3-targeted clinical programs, including TTI-101 and TTI-109.
On Stock Titan, Tvardi’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the key points in lengthy filings such as registration statements and current reports. Users can quickly identify items related to clinical trial disclosures, capital structure, compensation plans, and other material events, and can also monitor how Tvardi describes the progress and risks associated with its STAT3 inhibitor programs over time.
Tvardi Therapeutics, Inc. reported that one of its officers, serving as Principal Accounting Officer, received an employee stock option grant. The option allows the officer to buy 4,000 shares of common stock at an exercise price of $4.2 per share, with a stated expiration date of December 16, 2035.
According to the vesting terms, 25% of the option shares will vest on December 16, 2026. The remaining shares will then vest in equal monthly installments over the following 36 months, as long as the officer continues to provide service through each vesting date. After this grant, the officer beneficially owns 4,000 derivative securities directly.
Tvardi Therapeutics, Inc. Chief Medical Officer, filing as a single reporting person, reported a new grant of employee stock options. On 12/16/2025, the officer received an option to purchase 17,500 shares of common stock at an exercise price of $4.2 per share, held as direct ownership. The option expires on 12/16/2035.
According to the vesting terms, 25% of the shares subject to the option will vest on December 16, 2026. The remaining 75% will then vest in equal monthly installments over the following 36 months, conditioned on the officer’s continuous service through each vesting date.
Tvardi Therapeutics, Inc. reported an insider equity award to its Chief Financial Officer on a Form 4. The CFO received an employee stock option giving the right to buy 17,500 shares of common stock at an exercise price of $4.2 per share, granted on 12/16/2025 and expiring on 12/16/2035.
According to the vesting terms, 25% of the option shares vest on December 16, 2026. The remaining shares vest in equal monthly installments over the following 36 months, as long as the executive remains in continuous service through each vesting date. The transaction is reported as directly owned by the CFO and reflects standard stock-based compensation rather than an open-market stock purchase or sale.
Tvardi Therapeutics, Inc. reported that its Chief Executive Officer and director received an employee stock option grant. On December 16, 2025, the insider was granted an option to purchase 47,500 shares of common stock at an exercise price of $4.2 per share, with an expiration date of December 16, 2035.
According to the vesting schedule, 25% of the shares underlying the option will vest on December 16, 2026. The remaining shares will then vest in equal monthly installments over the following 36 months, conditioned on the reporting person’s continuous service with the company through each vesting date.
Tvardi Therapeutics, Inc. reported that it has made an updated corporate presentation available on its website. The company describes this as a general information update under Regulation FD, aimed at providing the same information to all market participants at the same time.
The updated presentation is also furnished as an exhibit to the current report, dated November 19, 2025. Because it is furnished rather than filed, the material is not subject to certain liability provisions of the federal securities laws and is not automatically incorporated into other regulatory submissions.
Tvardi Therapeutics, Inc. filed a prospectus supplement covering the resale by certain selling stockholders of up to 2,084,117 shares of common stock issued under the December 17, 2024 Merger Agreement with Cara Therapeutics. The supplement updates the base prospectus with information from the company’s Q3 2025 Form 10‑Q.
The common stock trades on Nasdaq as “TVRD.” The last quoted sale price on November 12, 2025 was $4.24. Shares outstanding were 9,381,344 as of November 10, 2025.
The attached 10‑Q reports a net loss of $5.5 million for the quarter and $10.9 million for the nine months ended September 30, 2025, cash and cash equivalents of $21.4 million and short‑term investments of $15.0 million. Management states that conditions raise substantial doubt about the company’s ability to continue as a going concern. The 10‑Q also notes preliminary Phase 2 data in IPF for TTI‑101 did not meet study goals, with further analyses ongoing.
Tvardi Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results and business highlights for the fiscal quarter ended September 30, 2025. The company issued the press release on November 13, 2025, and attached it as Exhibit 99.1.
The information about results and highlights is furnished under Item 2.02 of the Exchange Act and is not deemed filed or incorporated by reference into other SEC filings. The report also includes an Inline XBRL cover page as Exhibit 104.
Tvardi Therapeutics (TVRD) filed its Q3 2025 report, showing a net loss of $5.5 million for the quarter. Operating expenses were driven by research and development of $3.6 million and general and administrative of $2.3 million. Interest income was $0.4 million.
Liquidity remains a key focus. The company reported cash and cash equivalents of $21.4 million and short‑term investments of $15.0 million as of September 30, 2025. Cash used in operating activities was $17.8 million for the nine months. Management disclosed conditions that raise substantial doubt about the company’s ability to continue as a going concern.
Tvardi completed a reverse recapitalization with Cara Therapeutics on April 15, 2025, adding $24.992 million of cash and converting the company’s Convertible Notes into 1,265,757 shares, with a $7.8 million fair value gain recognized year‑to‑date. A subsequent event noted that the Phase 2 IPF study of TTI‑101 did not meet its goals on October 13, 2025. Common shares outstanding were 9,381,344 as of November 10, 2025.
Tvardi Therapeutics, Inc. filed a Form S-8 to register shares for employee equity plans. The filing registers 715,934 shares of common stock under the 2018 Stock Incentive Plan, 935,554 shares under the 2025 Equity Incentive Plan, and 93,555 shares under the 2025 Employee Stock Purchase Plan.
The company explains that on April 15, 2025, Cara Therapeutics, Inc. completed a merger with Tvardi, after which Cara changed its name to Tvardi Therapeutics, Inc. and assumed Tvardi’s 2018 Plan. Outstanding Legacy Tvardi stock options were converted into options to purchase Tvardi Therapeutics common stock.
The filing also outlines director and officer indemnification provisions under Delaware law and references governing corporate documents and plan exhibits incorporated by reference.
Tvardi Therapeutics (TVRD) filed Amendment No. 2 to a Form S-1 to register the resale of up to 2,084,117 shares of common stock issued to certain holders in connection with its April 2025 merger. The company states it will not receive any proceeds from sales under this prospectus; selling stockholders will pay any commissions and discounts.
The shares may be sold from time to time using various methods and prices. Tvardi’s common stock trades on Nasdaq as TVRD; the last quoted sale price was $6.58 on October 17, 2025. Following the merger and a 1‑for‑3 reverse stock split, 9,355,542 shares were issued and outstanding immediately after the effective time.
Tvardi is a clinical‑stage biopharma developing oral STAT3 inhibitors. Lead candidate TTI‑101 is in Phase 2 for HCC with FDA Fast Track and orphan designations; the company reported preliminary Phase 2 IPF data in October 2025 and concluded the study did not meet its goals. Risk disclosures note substantial doubt about the company’s ability to continue as a going concern and the need for additional capital.